India supplies approximately 20% of the world's generic medicine volume — 200+ countries receive Indian-made tablets, capsules, injectables, and APIs. The Pharmexcil export figure of USD 27.9 billion for FY2023-24 is impressive enough. But the domestic opportunity is equally significant: India's domestic pharmaceutical market is one of the world's largest by volume — serving 1.4 billion people under Ayushman Bharat, PMBJP (Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana), the National Health Mission, and private healthcare — at some of the lowest drug prices in the world. Behind both the export and domestic market lies a manufacturing ecosystem of formulation plants, API manufacturers, and drug intermediate producers — each of which is a business that an entrepreneur with chemis

...

India supplies approximately 20% of the world's generic medicine volume — 200+ countries receive Indian-made tablets, capsules, injectables, and APIs. The Pharmexcil export figure of USD 27.9 billion for FY2023-24 is impressive enough. But the domestic opportunity is equally significant: India's domestic pharmaceutical market is one of the world's largest by volume — serving 1.4 billion people under Ayushman Bharat, PMBJP (Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana), the National Health Mission, and private healthcare — at some of the lowest drug prices in the world. Behind both the export and domestic market lies a manufacturing ecosystem of formulation plants, API manufacturers, and drug intermediate producers — each of which is a business that an entrepreneur with chemistry knowledge and regulatory understanding can enter.

India's pharmaceutical industry is valued at approximately USD 50 billion (domestic + exports) in FY2023-24 (Ministry of Chemicals and Fertilisers / DPIIT), growing at 10–12% annually. The sector has 3,000+ pharmaceutical manufacturers and 10,500+ manufacturing units (CDSCO data). It is the world's largest supplier of generic medicines by volume, the third-largest by value (Pharmexcil), and produces 80% of the world's antiretroviral drugs. For a pharmaceutical manufacturing entrepreneur, this scale represents both the market opportunity and the competitive context: the Indian pharma market is sophisticated, regulated, and increasingly quality-driven, but also one of the most MSME-accessible pharmaceutical markets in the world through the generic drug licensing framework.

At a Glance: Pharmaceutical and Fine Chemicals Business in India India Pharma Industry Size (FY2023-24): ~USD 50 billion domestic + export; growing at 10–12% — Ministry of Chemicals and Fertilisers / DPIIT India Pharma Exports (FY2023-24): ~USD 27.9 billion — Pharmexcil / DGCI&S PLI Scheme for Pharmaceuticals (Bulk Drugs + Formulations): Rs. 15,000 crore (Bulk Drugs PLI) + Rs. 15,000 crore (Formulations PLI) — Ministry of Chemicals PM Pharma Scheme (Pharma Clusters): 3 Bulk Drug Parks; 4 Medical Device Parks — Ministry of Chemicals India Generic Drug Market: 60,000+ generic brands; 3,000+ manufacturers — CDSCO / Ministry of Health Key Licence: CDSCO Drug Manufacturing Licence (Form 25/28 under Drugs and Cosmetics Act) + WHO-GMP or Schedule M compliance + NABL-accredited QC lab + PCB Red category consent

Why Pharmaceutical and Fine Chemicals Manufacturing Is One of India's Highest-Opportunity MSME Sectors

Pharmaceutical and drug intermediate manufacturing in India is supported by the most government-backed incentive structure of any manufacturing sector: the Rs. 15,000 crore PLI for Bulk Drugs (Ministry of Chemicals) targeting 53 critical Active Pharmaceutical Ingredients (APIs); the Rs. 15,000 crore PLI for Pharmaceutical Formulations targeting complex generics, biosimilars, and patented drug technology; three dedicated Bulk Drug Parks with government-funded shared infrastructure; and the PMBJP network of 10,000+ Jan Aushadhi kendras that create a guaranteed domestic distribution channel for generic medicine manufacturers.

The PLI Scheme for Bulk Drugs identifies 53 Active Pharmaceutical Ingredients (APIs) currently imported — primarily from China — where India needs domestic manufacturing capability. These include: fermentation-based APIs (Penicillin G, 6-APA, 7-ACCA), key starting materials (KSMs), and drug intermediates in anti-infective, cardiovascular, anti-diabetic, and anti-cancer categories. The PLI provides 10–20% incentive on incremental sales above a base year for 6 years. For a chemist-entrepreneur with knowledge of organic synthesis or fermentation technology, targeting one or two of the 53 PLI APIs is the highest-support-level manufacturing entry in the Indian MSME ecosystem.

The PMBJP (Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana) programme has created 10,000+ Jan Aushadhi generic medicine stores across India (Ministry of Chemicals), selling CDSCO-approved generic medicines at 50–90% below branded drug prices. These stores source from government-approved generic drug manufacturers — creating a structured, government-procurement buyer for generic medicine formulation MSMEs who obtain CDSCO Drug Manufacturing Licence and produce WHO-GMP compliant drugs at competitive costs.

Ayushman Bharat PM-JAY (Ministry of Health) covers 55 crore beneficiaries (National Health Authority data) for hospitalisation insurance at empanelled hospitals. These hospitals procure medicines through the government's Health Management Information System and through Central Drugs and Medical Supplies Corporation (CDMSC) procurement. MSME generic medicine manufacturers listed on government procurement platforms serve this enormous subsidised demand. Every National Health Mission medicine procurement round is a significant sales opportunity for registered MSME drug formulation manufacturers.

PLI for Bulk Drugs: Rs. 15,000 Crore and 53 Critical APIs — India's Pharmaceutical Independence Programme India imports approximately 70% of its API (Active Pharmaceutical Ingredient) raw material requirements, predominantly from China. The COVID-19 pandemic exposed the supply chain vulnerability of this dependence. The government's response: PLI Scheme for Promotion of Domestic Manufacturing of Critical KSMs / Drug Intermediates and APIs (Ministry of Chemicals and Fertilisers), with Rs. 15,000 crore allocated for production incentives of 10–20% on incremental sales for 6 years. The scheme targets 53 specific APIs across 3 categories: fermentation-based (antibiotics, vitamins), chemical synthesis-based (cardiovascular, anti-diabetic), and other critical APIs. Approved beneficiaries include both large pharma and MSME-scale manufacturers. Additionally, three Bulk Drug Parks — each with government-funded common infrastructure (effluent treatment, solvent recovery, utilities) — are being developed in Himachal Pradesh, Gujarat, and Andhra Pradesh to provide MSME bulk drug manufacturers with world-class shared infrastructure at subsidised cost. (Ministry of Chemicals and Fertilisers; PLI Bulk Drugs scheme notification)

Market Demand, Growth and Statistical Evidence

India's pharmaceutical market is growing across domestic formulations, API exports, and the emerging biosimilars and complex generics segment.

Domestic pharmaceutical market: India's domestic pharma market at approximately Rs. 2.3 lakh crore in FY2023-24 (Pharmexcil domestic estimate) is growing at 9–11% annually. The domestic market is driven by: NHM (National Health Mission) medicine procurement for public health facilities; PMBJP Jan Aushadhi generic prescribing; Ayushman Bharat hospital procurement; and private prescription market growth with rising chronic disease burden (diabetes, hypertension, oncology).

Year-Wise India Pharmaceutical Market Data (Ministry of Chemicals / Pharmexcil)

Year	Pharma Exports (USD Bn)	Domestic Market (Rs. Lakh Cr)	API Market (USD Bn)
FY2019-20	~20.6	~1.71	~3.5
FY2020-21	~24.4 (COVID boost)	~1.79	~3.8
FY2021-22	~24.6	~1.94	~4.0
FY2022-23	~25.0	~2.10	~4.3
FY2023-24	~27.9	~2.30	~4.8
FY2025 (est.)	~31.0	~2.55	~5.5
FY2027 (forecast)	~38.0	~3.10	~6.8
FY2030 (forecast)	~55.0	~4.00	~9.0
FY2033 (forecast)	~72.0	~5.10	~11.5
FY2035 (forecast)	~85.0	~6.20	~14.0

Note: Export data from Pharmexcil / DGCI&S. Domestic market estimates from Pharmexcil and Ministry of Chemicals. API market estimate from DPIIT / Ministry of Chemicals. FY2035 is stated estimate using assumed 12% CAGR for exports and 10% for domestic market.

Jan Aushadhi: 10,000+ Generic Medicine Stores Creating a Guaranteed Domestic Market for MSME Drug Manufacturers The PMBJP (Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana), Ministry of Chemicals and Fertilisers, operates over 10,000 Jan Aushadhi generic medicine stores across India (as of 2024), selling CDSCO-approved generic medicines at 50–90% below branded drug prices. The Bureau of Pharma Public Sector Undertakings of India (BPPI) manages the procurement of generic medicines for Jan Aushadhi stores. BPPI issues procurement notices for generic drug manufacturers who meet CDSCO WHO-GMP standards — providing a structured government buyer channel. In FY2023-24, Jan Aushadhi stores achieved sales of approximately Rs. 2,000 crore in generic medicines (Ministry of Chemicals data). For an MSME formulation manufacturer producing common generic medicines (analgesics, antibiotics, antacids, anti-diabetics) with CDSCO Drug Manufacturing Licence and Schedule M GMP compliance, BPPI procurement is the most accessible, lower-competition government buyer channel in the pharmaceutical sector. (Ministry of Chemicals; BPPI; PMBJP Annual Report)

What Government Data Reveals About the Pharma and Fine Chemicals Opportunity

Ministry of Chemicals, CDSCO, NHA (National Health Authority), and Pharmexcil data together define a regulatory and market landscape that is among the most data-rich of any Indian manufacturing sector.

CDSCO (Central Drugs Standard Control Organisation), Ministry of Health: India has approximately 3,000+ pharmaceutical manufacturers and 10,500+ manufacturing units licensed under the Drugs and Cosmetics Act (CDSCO Annual Report). The licensing framework distinguishes between bulk drug (API) manufacturers and formulation manufacturers — an MSME can enter either segment with appropriate Drug Manufacturing Licence (DML) under the D&C Act. CDSCO's Schedule M (WHO-GMP equivalent for domestic market) and WHO-GMP (required for export to regulated markets) are the quality benchmarks that all manufacturers must meet.

NHA (National Health Authority), Ministry of Health: Ayushman Bharat PM-JAY covers 55 crore beneficiaries across 12+ crore families (NHA Annual Report 2024). Each PM-JAY hospitalisation episode triggers drug procurement by empanelled hospitals. The NHM Essential Medicines List (EML) defines 348 medicines procured by government health facilities — each EML medicine category is a buyer-guaranteed market for WHO-GMP compliant generic manufacturers who are registered on government procurement portals.

Government & Department Statistics: Pharmaceutical and Fine Chemicals Sector

Indicator	Figure	Source & Year
India Pharma Exports (FY2023-24)	~USD 27.9 billion	Pharmexcil / DGCI&S
India Pharma Domestic Market (FY2023-24)	~Rs. 2.3 lakh crore	Pharmexcil / Ministry of Chemicals
CDSCO Licensed Drug Manufacturers	3,000+ companies; 10,500+ units	CDSCO Annual Report
PLI Bulk Drugs Allocation	Rs. 15,000 crore (53 critical APIs)	Ministry of Chemicals, PLI notification
PLI Pharmaceutical Formulations Allocation	Rs. 15,000 crore	Ministry of Chemicals, PLI notification
Jan Aushadhi Stores	10,000+	Ministry of Chemicals / BPPI, 2024
Jan Aushadhi Sales (FY2023-24)	~Rs. 2,000 crore	Ministry of Chemicals / BPPI Annual Report
PM-JAY Beneficiaries	55 crore people	National Health Authority (NHA) 2024
Bulk Drug Parks Approved	3 parks (HP, Gujarat, AP)	Ministry of Chemicals

Government Schemes and Incentives for Pharmaceutical Manufacturers

1. PLI Scheme for Bulk Drugs (Ministry of Chemicals): Rs. 15,000 crore for domestic production of 53 critical APIs. Incentive: 10–20% on incremental sales for 6 years. Minimum investment threshold applies per API category. Apply through DPIIT PLI portal. MSMEs in fermentation-based APIs (Penicillin, Vitamin C) are specifically included.

2. PLI Scheme for Pharmaceutical Formulations: Rs. 15,000 crore targeting complex generics (injectables, depot formulations, inhalers), biosimilars, and patented drug technology. MSME-scale manufacturers targeting hospital injectables or specialty generics qualify if they meet the investment and turnover thresholds in the PLI notification.

3. Bulk Drug Parks (Ministry of Chemicals): Three Bulk Drug Parks in HP (Himachal Pradesh), Gujarat, and Andhra Pradesh with government-funded common infrastructure: solvent recovery, ETP, utilities, warehousing, and testing labs. MSME API manufacturers in approved Bulk Drug Parks access this infrastructure at subsidised cost — reducing individual investment requirement for environment, health, and safety compliance.

4. PM Pharma Scheme (BPPI / PMBJP): BPPI procurement from CDSCO WHO-GMP compliant manufacturers for Jan Aushadhi stores. MSME manufacturers applying for BPPI vendor registration can supply generic medicines to 10,000+ Jan Aushadhi outlets — accessing government-guaranteed volume without retail distribution investment.

5. DPIIT MSME Credit and Cluster Support: Pharma clusters (Hyderabad, Ahmedabad / Ankleshwar, Haridwar, Baddi) benefit from cluster development programme support — common testing facilities, shared ETP, regulatory compliance training. MSME pharma manufacturers in cluster locations access shared infrastructure that is otherwise prohibitively expensive for individual small units.

Import and Export Opportunity in Pharmaceuticals and Fine Chemicals

India is the world's largest generic drug exporter and a major fine chemicals exporter — with specific import substitution gaps in key starting materials (KSMs) and novel drug intermediates.

India's pharmaceutical exports at USD 27.9 billion in FY2023-24 (Pharmexcil) go to: USA (largest market, ~31% of exports), Africa (23%), Europe, and other markets. India exports finished generic formulations (tablets, capsules, injectables), APIs, and drug intermediates. The US is the most valuable market — USFDA-approved Indian plants supply ANDA (Abbreviated New Drug Application) filed generic drugs to the US retail pharmacy market at scale. Every USFDA approval for an Indian drug plant opens the most regulated and highest-margin export market in global generics.

Import substitution: India imports Key Starting Materials (KSMs) for antibiotics (Penicillin G, 7-ACA), vitamins (Vitamin B12), and cardiovascular APIs from China — the PLI Bulk Drug scheme specifically targets reducing this import dependence. An MSME manufacturer producing one or two KSMs for domestic API manufacturers (who then produce the finished API) occupies a protected, import-substituting position in the domestic pharma supply chain.

Major Indian Pharmaceutical Companies

Company	Segment / Note
Sun Pharmaceutical (Mumbai)	India's largest pharma; specialty + generics; listed; USFDA approved
Dr. Reddy's Laboratories (Hyderabad)	API + formulations; listed; USFDA approved; major exporter
Cipla (Mumbai)	Respiratory + HIV + generics; listed; API + formulation
Lupin (Mumbai)	Formulations + API; listed; US generics market leader in several categories
Aurobindo Pharma (Hyderabad)	API + formulations; listed; largest penicillin producer
Divi's Laboratories (Hyderabad)	Custom synthesis API + fine chemicals; listed; global pharma supply
IPCA Laboratories (Mumbai)	Anti-malarial API + formulations; listed; strong BPPI supplier
MSME bulk drug units (Hyderabad, Ahmedabad, Haridwar)	API and drug intermediates MSMEs; PLI and cluster beneficiaries

The Growth Horizon: Pharmaceutical Manufacturing to 2035

India's pharmaceutical exports are on track to reach USD 85 billion by 2035 (stated estimate at 12% CAGR) as: complex generic approvals in the US market expand revenue per product; biosimilar manufacturing capability grows with government BIRAC funding; and the API import substitution programme reduces dependence on Chinese supply, enabling more competitive domestic API pricing. India's domestic market at Rs. 6+ lakh crore by 2035 will be driven by Ayushman Bharat's expanding coverage, the NHM's primary healthcare expansion, and the chronic disease burden of an ageing population.

Fine chemicals — the chemicals used in drug synthesis, agrochemicals, dye manufacturing, and specialty industrial applications — will grow with India's pharmaceutical output and the global shift of chemical supply chains away from China. India's DPIIT has identified fine chemicals as a priority import substitution sector; the PLI for Chemicals (under discussion) or the Specialty Chemicals PLI may provide additional incentives for MSME fine chemical manufacturers who supply the pharmaceutical supply chain.

CDSCO Licensing Reality: The Regulatory Roadmap Before the First Tablet Is Made Pharmaceutical manufacturing is India's most regulated manufacturing sector. The minimum regulatory preparation before starting production: (1) Drug Manufacturing Licence (DML) from CDSCO or State Licensing Authority (SLA) — Form 25 for new drug formulation manufacture, Form 28 for loan licence (third-party manufacturing). (2) Schedule M GMP compliance for domestic market; WHO-GMP certification for BPPI, NHM, and export supply. (3) Drug Testing Laboratory registration with CDSCO for in-house QC. (4) PCB Red category consent (most pharma manufacturing is classified as Red category). (5) Factory Act registration. Budget 12–24 months and Rs. 50 lakh–Rs. 2 crore for complete regulatory readiness before commercial production begins. Regulatory shortcuts in pharmaceutical manufacturing have serious legal and reputational consequences — invest fully in compliance infrastructure.

Practitioner Q&A: Pharmaceutical and Fine Chemicals Manufacturing

Q1: What is the most accessible entry point in pharmaceutical manufacturing for a first-time MSME?

Generic tablet and capsule formulation under a loan licence is the most accessible starting point. A loan licence (Form 28) permits a manufacturer to produce drugs in another licensed facility (a contract manufacturer with approved premises) — eliminating the upfront cost of building a GMP-compliant manufacturing facility. The entrepreneur obtains a Drug Manufacturing Licence (DML) in their name, contracts production to an approved facility, and sells drugs under their brand or as a generic manufacturer to Jan Aushadhi (BPPI), state government health procurement, or private wholesale. Investment for a loan licence pharma company: Rs. 10–50 lakh (regulatory fees, product testing, packaging, marketing). The loan licence model enables market entry and brand building before committing capital to own manufacturing infrastructure.

Q2: What CDSCO licences are needed to manufacture pharmaceutical drugs?

Drug manufacturing in India is governed by the Drugs and Cosmetics Act 1940 and Rules thereunder. Drug Manufacturing Licence (Form 25) is issued by the State Licensing Authority (Drugs Controller of the respective state) for manufacturing facilities meeting Schedule M GMP requirements. WHO-GMP Certificate is issued by CDSCO (central) or SLA (state) after inspection of the facility against WHO Technical Report Series (TRS) 902 / 961 standards — required for supply to BPPI, NHM procurement, and regulated market exports. New drug formulation or new API requires prior product approval from CDSCO (Form 44 application). The Drug Master File (DMF) filed with USFDA is required for US API export. PCB Red category consent is required for most pharmaceutical manufacturing operations.

Q3: What is the API (Active Pharmaceutical Ingredient) manufacturing opportunity?

API manufacturing involves chemical synthesis, fermentation, or semi-synthesis of the active molecule that provides a drug's therapeutic effect. MSMEs entering API manufacturing typically target: (1) Simple chemical synthesis APIs — analgesics (paracetamol KSMs), antacids (ranitidine intermediates), vitamins (ascorbic acid intermediates); (2) Fermentation-based APIs — penicillin G, ampicillin, erythromycin — where India has a historical competitive advantage in fermentation scale-up; (3) Custom synthesis for research and pharmaceutical companies — producing small batches of novel drug intermediates or lab chemicals for research buyers. The PLI for Bulk Drugs provides specific financial support for 53 critical API categories. Apply through the Ministry of Chemicals PLI portal for applicable API categories.

Q4: What is the BPPI vendor registration process for Jan Aushadhi supply?

BPPI (Bureau of Pharma Public Sector Undertakings of India) issues procurement notices for generic medicines on its website and through the Government e-Marketplace (GeM). To qualify as a BPPI supplier: obtain a valid Drug Manufacturing Licence (Form 25) from the state SLA; achieve Schedule M GMP compliance (verified by SLA inspection); submit product dossiers (formulation composition, manufacturing process, in-process and finished product specifications) to BPPI for each product; pass BPPI quality audit of manufacturing facility; and offer products at prices below BPPI's defined procurement rates. Once registered, BPPI places purchase orders for specific quantities. Jan Aushadhi is a recurring procurement programme — once registered, annual orders are expected as the programme expands.

Q5: What is the specialty chemicals opportunity for pharma supply chain?

Fine and specialty chemicals serving the pharmaceutical supply chain include: pharmaceutical excipients (microcrystalline cellulose, lactose, povidone, croscarmellose sodium — used as tablet binders, disintegrants, fillers); pharmaceutical solvents (methanol, ethanol, isopropanol, acetone, ethyl acetate in pharma grade purity); laboratory reagents and analytical standards for QC laboratories; and packaging chemicals (PVDC coating for blister films, aluminium foil printing inks for pharma packaging). An MSME producing pharmaceutical-grade excipients or solvents for bulk sale to formulation manufacturers does not require a Drug Manufacturing Licence (these are not drug products) — but does require ISO 9001 quality system, NABL-accredited testing, and buyer GMP audit compliance. This is a lower-regulatory-burden pharma supply chain entry compared to direct drug manufacturing.

Q6: What is the nutraceutical and ayurvedic product manufacturing opportunity?

Nutraceuticals (dietary supplements, vitamins, protein powders, omega-3 capsules) and Ayurvedic medicines are regulated separately from allopathic pharmaceuticals: nutraceuticals under FSSAI Food Safety Regulations; Ayurvedic medicines under the Drugs and Cosmetics Act Schedule E (Ayurvedic formulations) with licensing from state AYUSH departments. Nutraceutical manufacturing has significantly lower regulatory barriers than allopathic drug manufacturing — FSSAI Central Licence (turnover > Rs. 20 crore) or State Licence (below), GMP compliance under Schedule 2 of Food Safety Regulations, and NABL-tested product QC. India's nutraceutical market is growing at 15%+ annually (FSSAI / DPIIT estimate) with the post-COVID health supplement consumption surge being sustained by ongoing consumer health awareness.

Q7: What are the export-oriented pharma manufacturing models for MSMEs?

Three export models for MSME pharmaceutical manufacturers: (1) Contract manufacturing for export-licensed companies — produce drugs under loan licence for established export-licensed pharma companies who manage the USFDA/EU GMP approvals. The MSME manufacturer receives manufacturing fees and does not manage regulatory approvals. (2) Generic drug export to semi-regulated markets — Africa (Kenya, Tanzania, Nigeria), SAARC, and Southeast Asian markets have less stringent drug regulatory requirements than the US or EU. WHO-GMP certification is the primary credential for these markets. (3) API export — Indian APIs exported to EU and US must meet EDQM (European Directorate for Quality of Medicine) or USFDA drug master file (DMF) standards. API export to EU requires CEP (Certificate of Suitability). Pharmexcil membership provides export market facilitation and buyer introduction support.

Q8: What is the drug intermediate manufacturing opportunity?

Drug intermediates are chemical compounds produced during the synthesis of an API — they are not the final active ingredient but essential steps in the synthesis pathway. India currently imports significant volumes of drug intermediates from China, particularly for antibiotics (6-APA, 7-ADCA, 7-ACCA), anti-retroviral drugs (efavirenz intermediates), and cardiovascular drugs. The PLI for Bulk Drugs includes key starting materials (KSMs) and drug intermediates in its targeted categories. An MSME drug intermediate manufacturer targeting one or two PLI-covered intermediates can receive PLI financial support while serving domestic API manufacturers seeking to reduce China dependence. Chemistry knowledge, process scale-up capability, and PCB Red category compliance are the core requirements.

Q9: What NABL-accredited testing requirements apply to drug manufacturers?

NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation is required for a drug testing laboratory to have its test results recognised by CDSCO, BPPI, and regulated market export buyers. Every drug manufacturer must either have an in-house NABL-accredited QC laboratory or send samples to an external NABL-accredited contract testing laboratory. Testing requirements for finished dosage forms: identity, assay, dissolution, related substances, microbial limit test, and packaging integrity. For APIs: identity, assay, impurity profile, residual solvents, particle size (where relevant). NABL accreditation for an in-house lab: application to NABL through its online portal; technical assessor visit; budget Rs. 5–15 lakh for accreditation process and annual maintenance. The in-house NABL lab is a quality signal to all regulated buyers.

Q10: What are the NHM (National Health Mission) procurement channels for drug manufacturers?

NHM (National Health Mission), Ministry of Health: state NHM health societies procure medicines for public health facilities through state-level tender processes. The Essential Medicines List (EML) defines the 348 medicines eligible for procurement. Manufacturers must be registered with the state health department's approved vendor list (AVL) — which requires WHO-GMP facility inspection and price quotation below L1 (lowest) tender discovery price. Tamil Nadu Medical Services Corporation (TNMSC), Rajasthan Medical Services Corporation (RMSC), Karnataka SUVARNA AROGYA SURAKSHA TRUST, and other state procurement agencies issue annual or biannual tenders. Winning an NHM state tender provides 6–12 months of assured volume — a significant revenue base for an MSME formulation manufacturer.

Q11: What is the difference between Schedule M compliance and WHO-GMP certification?

Schedule M is the Indian GMP standard — prescribed under the Drugs and Cosmetics Act 1940 and mandatory for all drug manufacturers in India for domestic market supply. It covers facility design, equipment qualification, process validation, quality management, and documentation. WHO-GMP is the internationally recognised GMP standard based on WHO Technical Report Series 902 and 961 — required for supply to BPPI Jan Aushadhi procurement, NHM export-linked procurement, and export to countries that accept WHO-GMP as the qualification standard (most African and SAARC markets). USFDA GMP (21 CFR Part 211) is more demanding than both and required for supply to the US market. USFDA inspection and approval opens the world's highest-value generic drug market. For MSME manufacturers starting domestically, Schedule M is the immediate target; WHO-GMP is the export readiness credential to aim for within 2–3 years of operation.

The Bottom Line

India's pharmaceutical sector at USD 50 billion and growing at 10–12% annually, backed by Rs. 30,000 crore in PLI incentives, three dedicated Bulk Drug Parks, 10,000+ Jan Aushadhi generic medicine stores, and Ayushman Bharat's 55-crore beneficiary base, offers the most comprehensively supported manufacturing opportunity of any Indian MSME sector from a government scheme perspective.

The single most accessible first step for a pharmaceutical entrepreneur is the loan licence (Form 28) model — start production in a contract manufacturer's GMP facility, build your brand and buyer relationships, and invest in own manufacturing infrastructure once validated market and revenue exist. This approach has produced hundreds of successful Indian generic drug companies.

Your most critical first steps: engage a qualified regulatory consultant to guide CDSCO licensing; identify your product portfolio from the NHM EML or BPPI product list; shortlist a contract manufacturer with Schedule M compliance; and register as a BPPI vendor. In pharmaceutical manufacturing, the regulatory licence is your manufacturing permit AND your market access credential — it comes before everything else.

References

• Ministry of Chemicals and Fertilisers, Government of India — PLI Scheme for Bulk Drugs (Rs. 15,000 crore; 53 critical APIs); PLI Scheme for Pharmaceutical Formulations (Rs. 15,000 crore); Bulk Drug Parks (HP, Gujarat, AP); Jan Aushadhi / BPPI annual procurement data
• CDSCO (Central Drugs Standard Control Organisation), Ministry of Health — Drug Manufacturing Licence (Form 25/28); Schedule M GMP standards; WHO-GMP certification norms; approved manufacturer data (3,000+ companies; 10,500+ units)
• Pharmexcil (Pharmaceuticals Export Promotion Council of India), Ministry of Commerce — India pharma exports (USD 27.9 billion FY2023-24); market-wise export data; WHO-GMP export certification facilitation
• NHA (National Health Authority), Ministry of Health — Ayushman Bharat PM-JAY beneficiary data (55 crore people; 12+ crore families); essential medicines procurement framework; empanelled hospital medicine procurement
• BPPI (Bureau of Pharma Public Sector Undertakings of India), Ministry of Chemicals — Jan Aushadhi store count (10,000+); sales data (Rs. 2,000 crore FY2023-24); BPPI vendor registration and procurement norms
• NABL (National Accreditation Board for Testing and Calibration Laboratories), Ministry of Science and Technology — NABL accreditation process for drug testing laboratories; scope of accreditation for pharmaceutical analysis